These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 26181424)
41. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523 [TBL] [Abstract][Full Text] [Related]
42. Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings? Egan G; Hamilton J; McKeown T; Bouffet E; Tabori U; Dirks P; Bartels U J Pediatr Hematol Oncol; 2020 May; 42(4):e248-e250. PubMed ID: 30676433 [TBL] [Abstract][Full Text] [Related]
43. Targeted Therapy for Neuroblastoma: ALK Inhibitors. Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094 [TBL] [Abstract][Full Text] [Related]
44. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Lee CI; Menzies AM; Haydu LE; Azer M; Clements A; Kefford RF; Long GV Melanoma Res; 2014 Oct; 24(5):468-74. PubMed ID: 25054915 [TBL] [Abstract][Full Text] [Related]
45. The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. Riehl LM; Schulte JH; Mulaw MA; Dahlhaus M; Fischer M; Schramm A; Eggert A; Debatin KM; Beltinger C Oncotarget; 2016 Feb; 7(6):6620-5. PubMed ID: 26735174 [TBL] [Abstract][Full Text] [Related]
46. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Seghers AC; Wilgenhof S; Lebbé C; Neyns B Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957 [TBL] [Abstract][Full Text] [Related]
47. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS. Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775 [TBL] [Abstract][Full Text] [Related]
48. Recurrent pelvic neuroblastoma in an adult patient. Loeser A; Gerharz EW; Riedmiller H Gynecol Oncol; 2007 Jul; 106(1):257-8. PubMed ID: 17466361 [TBL] [Abstract][Full Text] [Related]
50. Establishment of In Vivo Acquired Resistance to Chemotherapy Via Individual Dose Escalation Treatment Regime. Barker KT; Yogev O Methods Mol Biol; 2022; 2535():73-83. PubMed ID: 35867223 [TBL] [Abstract][Full Text] [Related]
51. Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7. Li J; Li J; Hu T; Cui X; Song Z; Shi X; Liu R Leuk Lymphoma; 2022 Sep; 63(9):2238-2242. PubMed ID: 35694895 [No Abstract] [Full Text] [Related]
52. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply. Zhu X; Cao Y; Zhang H Lancet Oncol; 2021 Oct; 22(10):e424. PubMed ID: 34592185 [No Abstract] [Full Text] [Related]
53. Role of surgery in neuroblastoma. Yoneda A Pediatr Surg Int; 2023 Apr; 39(1):177. PubMed ID: 37039977 [TBL] [Abstract][Full Text] [Related]
54. Two hits are better than one: rational dual strategy efficiently fights neuroblastoma. Zimmer J; Rolin C; Ollert M Signal Transduct Target Ther; 2024 Apr; 9(1):116. PubMed ID: 38688910 [No Abstract] [Full Text] [Related]
55. A historical overview of protein kinases and their targeted small molecule inhibitors. Roskoski R Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888 [TBL] [Abstract][Full Text] [Related]
56. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. Kang CW; Jang KW; Sohn J; Kim SM; Pyo KH; Kim H; Yun MR; Kang HN; Kim HR; Lim SM; Moon YW; Paik S; Kim DJ; Kim JH; Cho BC Mol Cancer Ther; 2015 Oct; 14(10):2238-48. PubMed ID: 26208525 [TBL] [Abstract][Full Text] [Related]
57. Trametinib: a MEK inhibitor for management of metastatic melanoma. Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842 [TBL] [Abstract][Full Text] [Related]